NAD+ at Home: Self-Administered Subcutaneous Protocols

NAD+ has spent the last decade migrating from research labs into longevity clinics and then, more recently, into home protocols supervised by licensed telehealth clinicians. The most common question patients ask is not whether NAD+ does something — the cellular biochemistry is well-characterized — but whether the at-home subcutaneous format can match the experience and signal of the clinic IV.

This article walks through how a prescribed at-home NAD+ protocol actually works: how patients are trained, how sterility is maintained outside a clinical setting, what the weekly schedule looks like, and what triggers an escalation from home dosing back to the clinic.

What NAD+ does, in brief

Nicotinamide adenine dinucleotide is a coenzyme present in every cell. It sits at the center of mitochondrial energy production, DNA-repair signaling through the PARP family, and sirtuin-mediated longevity pathways. Tissue NAD+ levels decline measurably with age — a 2018 cross-sectional study in human skin found roughly a 50 percent reduction in NAD+ from age 20 to age 60.¹ The clinical hypothesis behind exogenous NAD+ supplementation is that restoring substrate availability supports the enzymatic machinery that depends on it.

The IV format has dominated the clinic conversation for a decade because it bypasses the gut entirely and delivers a large bolus directly into circulation. The trade-off is well-known: a 60- to 90-minute infusion, often slowed further by chest pressure, abdominal cramping, or flushing if the rate is pushed. Subcutaneous protocols take a different approach.

Why subcutaneous, not IV, for at-home use

Subcutaneous administration delivers NAD+ into the fat layer beneath the skin, from which it absorbs into systemic circulation over hours rather than minutes. The pharmacokinetic profile is flatter — lower peak concentration, longer absorption tail — and most patients tolerate it dramatically better than the rapid IV push.

Three practical reasons subcutaneous is the format used at home:

• Tolerance. The flushing and abdominal-cramp response that IV NAD+ commonly provokes is largely a function of infusion rate. A 100 mg subcutaneous dose absorbing over four to six hours rarely produces those symptoms.
• Self-administration safety. Subcutaneous injection with a 31-gauge insulin needle is the same technique used by millions of insulin-dependent patients. IV access is not a self-administration technique.
• Cumulative weekly dosing. Two or three smaller subcutaneous sessions per week deliver a comparable or larger weekly milligram total than a single IV session, with steadier tissue exposure.

The clinical signal — the energy, sleep, and recovery effects patients describe — is built over the week, not delivered in a single session.

The onboarding visit

Every at-home NAD+ protocol starts with a video visit with a licensed clinician. The visit covers four things:

1. Eligibility review. Medical history, current medications, prior reactions to peptide therapy, and any contraindication that would route the patient to in-person care instead.
2. Goal setting. Recovery, sleep, training response, and subjective energy are the most common targets. The clinician sets expectations against what the protocol can and cannot do.
3. Injection demonstration. The clinician walks the patient through aspiration, skin preparation, the pinch-and-insert technique, depth, angle, and disposal. The patient performs the first injection on camera with the clinician watching.
4. Schedule and check-in cadence. A typical starting protocol is twice weekly for the first four weeks, with a clinician check-in at the four-week mark.

Most patients are confident after the supervised first injection. Those who are not get a second supervised session before transitioning to fully independent dosing.

Dose ranges and titration

There is no single right dose for subcutaneous NAD+. Published ranges vary widely, and clinical titration is patient-specific. Common starting protocols sit in the range of:

• 50 to 100 mg per injection
• Two to three injections per week
• Weekly total of 100 to 300 mg

Patients who tolerate the starting dose without significant injection-site reaction can be titrated up over four to eight weeks toward a higher per-session dose, often in 25 to 50 mg increments. Some patients respond well at the starting dose and never escalate. Others reach a session dose of 150 to 200 mg before the clinician signals diminishing returns.

The titration is conservative on purpose. NAD+ at higher per-session doses produces more flushing and a heavier sense of fatigue in the hour after injection. The clinician would rather hold a lower dose for an extra cycle than escalate prematurely and create a tolerance issue that derails the protocol.

Dose timing within the day

Subcutaneous NAD+ is typically injected in the morning or early afternoon. Two reasons:

• Energy effect. Many patients describe a subtle stimulant-like response in the hour after injection — not jittery, but alert. Evening injection can disrupt sleep onset for sensitive responders.
• Recovery support during training days. Patients who train hard often inject on training days specifically, timing the dose to support the post-session recovery window.

The dose timing is set during the onboarding visit and revisited at the four-week check-in based on patient-reported sleep, energy, and recovery patterns.

Sterility outside a clinical setting

Sterility is the part of at-home injection that draws the most concern from new patients. The protocol is designed to make it routine.

What ships from the pharmacy. Compounded NAD+ from a licensed 503A pharmacy arrives as either single-use vials or pre-filled single-use syringes, sealed and dated. The patient does not draw from multi-dose vials or reconstitute a powder.

What the patient supplies. A new alcohol prep pad per injection, a new sterile insulin-style needle each session if syringes are not pre-filled, and a sharps container for needle disposal. Sharps containers are available at most pharmacies and via household-hazardous-waste pickup.

What the protocol forbids. No needle reuse. No drawing from a multi-dose vial after the labeled stability window. No injection through clothing. No injection into tissue that is bruised, broken, or showing redness from a prior session.

The sterility profile of well-executed at-home subcutaneous injection is comparable to the sterility profile of insulin self-administration, which has decades of large-scale safety data behind it.

The weekly schedule

A representative four-week starting schedule looks like this:

• Week 1 — twice weekly. Monday and Thursday, 50 mg per session. The patient logs site, time, and any reactions.
• Week 2 — twice weekly. Same dose, same days. Confirm no significant injection-site reaction before considering escalation.
• Week 3 — clinician-determined. If tolerated, the dose may step to 75 mg per session. If the response is already strong at 50 mg, the dose holds.
• Week 4 — clinician check-in. Video visit reviewing energy, sleep, training response, and any side effects. The cadence may shift to three weekly sessions, or the dose may step to 100 mg, or both.

The site rotation matters. Patients rotate among at least four sites — left abdomen, right abdomen, left upper thigh, right upper thigh — to keep any single area from developing repeat irritation.

When to escalate to a clinic

The at-home protocol is designed to handle the routine case. It is not designed to substitute for in-person evaluation when something is unusual. The clinician will route the patient to local in-person care if any of the following occur:

• Persistent injection-site reaction. Redness or hardness at a site lasting more than 48 hours, or any sign of infection — warmth, expanding redness, drainage.
• Systemic reaction. Unexplained shortness of breath, chest pain, palpitations, or a rash beyond the injection site.
• No discernible response after eight weeks at a fully-titrated dose. This is a clinical question rather than an emergency, but it changes the conversation about whether NAD+ is the right protocol for the patient.
• A new clinical change unrelated to the protocol that the telehealth clinician cannot evaluate at the level needed.

The telehealth clinician can coordinate with a local primary-care provider in any of these cases. The home protocol is not a replacement for in-person care when in-person care is what the situation calls for.

How TelePeptide handles this

NAD+ at home runs inside the Foundation track for patients whose primary goals are recovery, sleep, and energy support. Eligibility is reviewed individually by a licensed clinician. The onboarding video visit is included. Compounded NAD+ ships in single-use sealed format from a licensed 503A pharmacy.

Compounded medications are prepared by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.

Footnotes

1. Massudi H, Grant R, Braidy N, et al. (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS ONE 7(7): e42357. DOI:10.1371/journal.pone.0042357. ↩